


RENAL BIOMARKERS

Without compromise

CYSTATIN C

***ENZYMATIC
CREATININE***



Cystatin C

Cystatin C

- *Avian Ig Y antibodies with no HAMA or RF interference*
- *Standard traceable to certified ERM-DA471/IFCC primary reference material*
- *Improved reliability in the detection of Chronic and Acute Kidney disease*

Enzymatic Creatinine

- *Reduced Interference*
- *Standard traceable NIST's SRM 967 IDMS Standard primary reference material*
- *Improved on-board and calibration stability*
- *Enzymatic methodology is a better clinical choice for the accurate measurement of creatinine, especially for neonates, pediatrics, and hematology units*

Enzymatic Creatinine


DIAZYME

The performance you need at a Cost Effective Price

	Cystatin C	Enzymatic Creatinine
Method	Latex Enhanced Immunoturbidometric avian IGY antibodies quantification at 540 nm	Advanced Trinder coupled enzymatic reaction with quantification at 550 nm
Traceability	Standard traceable to ERM-DA471/IFCC primary reference material	Standard traceable NIST's SRM 967 IDMS primary reference material
Method Correlation to Predicate	N = 45 r ² = 0.992 Slope = 0.999 y intercept of 0.0715.	Serum N = 55 r ² = 0.9981 Slope/Intercept: y = 0.9467x + 0.0643 Urine = 51 r ² = 0.9968 Slope/Intercept: y = 1.002x - 0.0518
Precision	Within-Run Precision Within-Laboratory Precision Less than 5%	Within-Run Precision Total Precision Less than 3% Serum/Urine
On-Board Stability *	Four weeks	Four weeks
Calibration Frequency	Two weeks	Two weeks
Calibrator	Liquid Stable 5 level	Liquid Stable single level
Linearity	0.2 to 8.0 mg/L.	Serum 0.14-13.56 mg/dL (12 - 1200 μmol/L) Urine 0.14 - 141.25 mg/dL (12 - 12500 μmol/L)
Instrument Specific Packaging	Roche Hitachi Beckman Synchron Beckman AU	Roche Hitachi Beckman Synchron Beckman AU

Cystatin C

- Enhanced sensitivity for acute and chronic kidney disease
- Independent of age, sex, race, lean muscle mass and diet
- Early detection of kidney damage due to adverse effects of potentially nephrotoxic medications such as contract media, cancer therapeutics or certain antibiotics
- Cystatin C is a strong predictor of incident CVD.
- Early detection and treatment improves patient outcomes in renal disease
- Shown to be a better prognostic marker than creatinine New Point of Care testing with Diazyme's SMART Cystatin C Test System
- Easy conversion of serum Cystatin C to eGFR with conversion ruler



Enzymatic Creatinine

- The enzymatic methodology is a better clinical choice than the Jaffé method for the accurate measurement of creatinine, especially for neonates, pediatrics, and hematology units
- Enzymatic method with significantly reduced interference compared to the Jaffé method
- Superior onboard and calibration stability and doesn't stain cuvettes like the Jaffé method
- Requires only eight (8) μL of sample ideal for pediatric and veterinary applications

Combined

Cystatin C - Enzymatic Creatinine eGFR Equation

- Performed better than either marker alone
- Provided more precise eGFR estimates



DIAZYME LABORATORIES

12889 Gregg Court, Poway, CA 92064 PO Box 85608, San Diego, CA 92186
Tel: 858-455-4768 888-DIAZYME WWW.DIAZYME.COM SALES@DIAZYME.COM